Sugi Predict

Sugi Predict / Compounds / SCHEMBL4482258

SCHEMBL4482258

SCHEMBL4482258

CCC(=O)N(CCN(C)C)c1ccc(N/C(=C2\C(=O)Nc3cc(F)ccc32)c2ccccc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 2/20 0.39
▸ FLT3 P36888 3/20 0.36
▸ PDGFRB P09619 2/20 0.35
▸ PDPK1 O15530 1/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ KDR P35968 2/20 0.33
▸ AURKA O14965 1/20 0.33
▸ PDGFRA P16234 1/20 0.33
▸ AURKB Q96GD4 1/20 0.33
▸ AURKC Q9UQB9 1/20 0.33
▸ TGM2 P21980 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ CASP3 P42574 3/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ CETP P11597 2/20 0.32
▸ PRKAA2 P54646 1/20 0.32
▸ PRKAA1 Q13131 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482260 1.00 BACE1 (0.39) BACE1FLT3PDGFRBPDPK1OPRM1
SCHEMBL4481348 0.93 TP53 (0.40) BACE1FLT3PDGFRBMAPTKDR
SCHEMBL4481354 0.93 TP53 (0.40) BACE1FLT3PDGFRBMAPTKDR
SCHEMBL4498295 0.92 BACE1 (0.38) BACE1FLT3PDGFRBMAPTKDR
SCHEMBL4498293 0.92 BACE1 (0.38) BACE1FLT3PDGFRBMAPTKDR
SCHEMBL4499513 0.91 BACE1 (0.41) BACE1FLT3PDGFRBMAPTKDR
SCHEMBL4499508 0.91 BACE1 (0.41) BACE1FLT3PDGFRBMAPTKDR
SCHEMBL4494308 0.91 BACE1 (0.41) BACE1FLT3PDGFRBMAPTKDR
SCHEMBL6182458 0.91 BACE1 (0.41) BACE1FLT3PDGFRBMAPTKDR
SCHEMBL4494303 0.91 BACE1 (0.41) BACE1FLT3PDGFRBMAPTKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 — — US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 — — US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 — — EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR BACE1 1615/4885FLT3 34/4885PDGFRB 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.